Neurology News and Research

Latest Neurology News and Research

Study: Mentally active lifestyle may protect against memory and learning problems in MS

A new study shows that a mentally active lifestyle may protect against the memory and learning problems that often occur in multiple sclerosis. The study is published in the June 15, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

15 Jun 2010

Parkinson’s disease linked to gene variant and pesticide: Study

Researchers from France reported in their new study that bad genes and exposure to certain banned pesticides could be blamed for development of Parkinson’s disease in men. In their study, published in the Archives of Neurology journal they show that men exposed to pesticides such as DDT and who had inherited genes for Parkinson’s disease were three and a half times more likely to develop Parkinson's than those with the normal version of the gene.

14 Jun 2010

Intellipharmaceutics International files Protonix ANDA with FDA

Intellipharmaceutics International Inc. today announced that is has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic of Protonix® (delayed release pantoprazole sodium). Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.

14 Jun 2010

National MS Society commits over $2.4M to support 7 CCSVI research projects

Over $2.4 million has been committed by the National MS Society (USA) and the MS Society of Canada to support 7 new research projects focusing on the role of CCSVI in MS.

14 Jun 2010

Study: Children with idiopathic onset epilepsy have high remission rate

A study conducted by researchers in The Netherlands confirmed that children with idiopathic new-onset epilepsy have a significantly higher rate of remission than those with remote symptomatic epilepsy.

14 Jun 2010

2010 GAPS sheds light on the painful reality of what life is like for gout patients

The 2010 Gout Attitudes Patient Survey, a new study of Americans with gout, released by Men's Health Network, sheds light on the painful reality of what life is like for the approximately five million Americans who live with this condition. Of those surveyed, 69 percent described the pain of a gout attack as "miserable," yet a quarter of gout patients feel that those without gout perceive them as overreacting to attacks, and 67 percent feel as though others do not take the condition seriously.

11 Jun 2010

APTA accredits Fox Rehabilitation to offer post-graduate residency training program in geriatrics

The American Physical Therapy Association has accredited Fox Rehabilitation to offer a new, post-graduate residency training program exclusively in geriatrics. Fox Rehabilitation is the only private physical therapy practice in the nation to receive this prestigious designation.

11 Jun 2010

World's largest DNA scan reveals new genetic changes in autistic children

The world's largest DNA scan for familial autism has uncovered new genetic changes in autistic children that are often not present in their parents. Identified in less than 1 percent of the population, these rare variants occur nearly 20 percent more in autistic children.

10 Jun 2010

Study: ChEI improves driving skills in patients with mild AD

A promising study from Rhode Island Hospital demonstrated that cholinesterase inhibitors, a type of medication often prescribed for Alzheimer's disease, improved some cognitive skills in patients with mild AD - skills that are necessary for driving. Findings from the study showed that after being treated with a ChEI, AD patients improved in some computerized tests of executive function and visual attention, including a simulated driving task.

10 Jun 2010

Men with MS may require education, support to manage their disease and therapy: Research

New research co-published by Saint Louis University and Express Scripts, Inc., suggests that men with multiple sclerosis may require more education and support to manage their disease and therapy than women with MS. Men also may benefit from more targeted adherence interventions.

10 Jun 2010

Helsinn Healthcare S.A., Eisai announce signing of licensing agreement

Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.

9 Jun 2010

New AAN guideline provides step-by-step process for determining brain death in adults

In an effort to create a uniform and accurate method for determining brain death, the American Academy of Neurology has issued an updated guideline that provides doctors with a step-by-step process for determining brain death in adults. The guideline is published in the June 8, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

9 Jun 2010

Impax reaches agreement with Endo and Penwest to settle pending litigation for OPANA ER

Impax Laboratories, Inc. today announced that it has reached agreement with Endo Pharmaceuticals and Penwest Pharmaceuticals to settle pending U.S. litigation with regard to the production and sale of generic formulations of OPANA ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.

9 Jun 2010

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Impax Laboratories, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen Idec and Elan Corporation, plc, in collaboration with EPI-Q, Inc. and Avatar International, LLC, today announced the launch of My MS Health, a first-of-its-kind, web-based, patient-reported outcomes research program. My MS Health is designed to track and provide instant reports on patient function and quality of life using validated measures over time.

9 Jun 2010

Optical coherence tomography shows promise for multiple sclerosis diagnosis

A quick, painless eye measurement shows promise as a way to diagnose multiple sclerosis in its very early stages, and to track the effectiveness of treatments, researchers from UT Southwestern Medical Center have found in a multicenter study.

8 Jun 2010

Excessive sleepiness more common in the U.S. than in Europe: Research

Excessive sleepiness is more common in the U.S. than in Europe, which raises concerns for public health and safety, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

Assured Pharmacy launches new website

Assured Pharmacy, a pharmacy service healthcare organization operating a chain of specialty pharmacies providing advanced prescription medication fulfillment solutions to sufferers of chronic pain, is pleased to announce the launch of its new website: www.assuredrxservices.com.

7 Jun 2010

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced today that complete phase 1/2 clinical data in two clinical studies of its lead oncology program, ANG1005, for the treatment of brain cancers, including glioblastoma (GBM) and brain metastases, were presented at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL.

7 Jun 2010